Summary

The global inhaled nitric oxide (iNO) market is on a robust growth trajectory, driven by rising incidences of respiratory disorders, increasing adoption of advanced therapies, and growing awareness of neonatal and critical care treatments. Inhaled nitric oxide, a selective pulmonary vasodilator, is widely used to manage conditions such as neonatal pulmonary hypertension, acute respiratory distress syndrome (ARDS), and chronic obstructive pulmonary disease (COPD). The market is anticipated to expand from $1.1 billion in 2026 to $2.1 billion by 2033, representing a compound annual growth rate (CAGR) of 9.90%.

Market Insights

Inhaled nitric oxide therapy has become a critical component in modern respiratory care due to its ability to improve oxygenation while minimizing systemic side effects. Its use in neonatal intensive care units (NICUs) for treating infants with persistent pulmonary hypertension of the newborn (PPHN) has significantly contributed to market growth. Additionally, integration with advanced ventilatory support systems in hospitals enhances treatment precision, making iNO therapy increasingly preferred among clinicians.

The market is further supported by ongoing clinical research and technological advancements in delivery systems. Cylinder-based, pipeline-integrated, and portable solutions have improved dosing accuracy, safety, and usability, enabling wider adoption in both neonatal and adult care settings.

Drivers

The inhaled nitric oxide market growth is underpinned by several key drivers:

1. Rising prevalence of respiratory diseases: Increasing incidences of COPD, ARDS, and other pulmonary conditions, along with factors such as aging populations, environmental pollution, and preterm births, are fueling demand for effective respiratory therapies like iNO.

2. Technological innovations in delivery systems: Modern delivery devices enhance precision, safety, and ease of use. Portable and automated systems facilitate broader hospital adoption, while digital integration allows real-time monitoring of therapy.

3. Expansion of neonatal and critical care markets: Rising awareness of neonatal pulmonary complications and increasing investments in critical care infrastructure are driving iNO therapy adoption. Hospitals are increasingly incorporating these therapies to improve survival rates and clinical outcomes.

4. Supportive regulatory environment: Regulatory approvals for expanded indications, coupled with stringent safety monitoring, have created a favorable environment for market growth. Agencies such as the FDA and EMA provide frameworks that promote safe and effective use of iNO therapy.

Business Opportunities

The inhaled nitric oxide market offers multiple growth opportunities for stakeholders, including pharmaceutical manufacturers, medical device companies, and healthcare providers. Emerging markets, particularly in Asia Pacific and Latin America, present untapped potential as awareness and access to neonatal and critical care therapies increase.

Innovation in iNO delivery systems presents additional avenues for business expansion. Integrating therapy with telemedicine and digital health solutions can enable real-time patient monitoring, personalized dosing, and reduced hospital stays. Moreover, advancements in personalized medicine allow for patient-specific treatment protocols, offering differentiation and competitive advantage for manufacturers and service providers.

Regional Analysis

North America dominates the global inhaled nitric oxide market, driven by high healthcare spending, advanced medical infrastructure, and early adoption of innovative respiratory therapies. Strong regulatory frameworks, robust reimbursement policies, and well-established neonatal care networks contribute to the region’s leadership.

Europe holds a substantial market share, fueled by investments in critical care facilities and increasing prevalence of respiratory disorders. Countries like Germany, France, and the UK are witnessing widespread adoption of iNO therapy in both neonatal and adult intensive care units.

Asia Pacific is expected to exhibit the fastest growth due to rising healthcare awareness, expanding hospital networks, and increasing incidences of respiratory diseases in countries such as China and India. Growing investment in neonatal and critical care services is expected to drive demand further.

Latin America and the Middle East & Africa are gradually embracing iNO therapy, supported by urban healthcare development, increasing availability of advanced treatments, and rising focus on neonatal care.

Key Players

The global inhaled nitric oxide market is highly competitive, with several established pharmaceutical and medical device companies driving innovation and market expansion. Key players include:

• Mallinckrodt Pharmaceuticals

• INO Therapeutics LLC

• Air Products and Chemicals, Inc.

• Vero Biotech LLC

• Linde plc

• Air Liquide S.A.

• BOC Limited

• Nikko Chemicals Co., Ltd.

• Cryo Life, Inc.

• GE Healthcare

• Philips Healthcare

• Siemens Healthineers

• Smiths Group plc

• CONBIO Medical Systems, Inc.

• Praxair, Inc.

These companies focus on strategic partnerships, product innovation, and mergers and acquisitions to strengthen their market presence and expand globally.

Market Segmentation

By Application

• Neonatal Respiratory Treatment

• Chronic Obstructive Pulmonary Disease

• Acute Respiratory Distress Syndrome

• Others

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Inhaled Nitric Oxide Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2026
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Fiver Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2025-2033
2.9.2. Price Impact Factors
3. Global Inhaled Nitric Oxide Market Outlook, 2020 - 2033
3.1. Global Inhaled Nitric Oxide Market Outlook, by Application, Value (US$ Bn), 2020-2033
3.1.1. Neonatal Respiratory Treatment
3.1.2. Chronic Obstructive Pulmonary Disease
3.1.3. Acute Respiratory Distress Syndrome
3.1.4. Others
3.2. Global Inhaled Nitric Oxide Market Outlook, by Region, Value (US$ Bn), 2020-2033
3.2.1. North America
3.2.2. Europe
3.2.3. Asia Pacific
3.2.4. Latin America
3.2.5. Middle East & Africa
4. North America Inhaled Nitric Oxide Market Outlook, 2020 - 2033
4.1. North America Inhaled Nitric Oxide Market Outlook, by Application, Value (US$ Bn), 2020-2033
4.1.1. Neonatal Respiratory Treatment
4.1.2. Chronic Obstructive Pulmonary Disease
4.1.3. Acute Respiratory Distress Syndrome
4.1.4. Others
4.2. North America Inhaled Nitric Oxide Market Outlook, by Country, Value (US$ Bn), 2020-2033
4.2.1. U.S. Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
4.2.2. Canada Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
4.3. BPS Analysis/Market Attractiveness Analysis
5. Europe Inhaled Nitric Oxide Market Outlook, 2020 - 2033
5.1. Europe Inhaled Nitric Oxide Market Outlook, by Application, Value (US$ Bn), 2020-2033
5.1.1. Neonatal Respiratory Treatment
5.1.2. Chronic Obstructive Pulmonary Disease
5.1.3. Acute Respiratory Distress Syndrome
5.1.4. Others
5.2. Europe Inhaled Nitric Oxide Market Outlook, by Country, Value (US$ Bn), 2020-2033
5.2.1. Germany Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
5.2.2. Italy Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
5.2.3. France Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
5.2.4. U.K. Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
5.2.5. Spain Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
5.2.6. Russia Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
5.2.7. Rest of Europe Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
5.3. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Inhaled Nitric Oxide Market Outlook, 2020 - 2033
6.1. Asia Pacific Inhaled Nitric Oxide Market Outlook, by Application, Value (US$ Bn), 2020-2033
6.1.1. Neonatal Respiratory Treatment
6.1.2. Chronic Obstructive Pulmonary Disease
6.1.3. Acute Respiratory Distress Syndrome
6.1.4. Others
6.2. Asia Pacific Inhaled Nitric Oxide Market Outlook, by Country, Value (US$ Bn), 2020-2033
6.2.1. China Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
6.2.2. Japan Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
6.2.3. South Korea Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
6.2.4. India Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
6.2.5. Southeast Asia Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
6.2.6. Rest of SAO Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
6.3. BPS Analysis/Market Attractiveness Analysis
7. Latin America Inhaled Nitric Oxide Market Outlook, 2020 - 2033
7.1. Latin America Inhaled Nitric Oxide Market Outlook, by Application, Value (US$ Bn), 2020-2033
7.1.1. Neonatal Respiratory Treatment
7.1.2. Chronic Obstructive Pulmonary Disease
7.1.3. Acute Respiratory Distress Syndrome
7.1.4. Others
7.2. Latin America Inhaled Nitric Oxide Market Outlook, by Country, Value (US$ Bn), 2020-2033
7.2.1. Brazil Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
7.2.2. Mexico Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
7.2.3. Argentina Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
7.2.4. Rest of LATAM Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
7.3. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Inhaled Nitric Oxide Market Outlook, 2020 - 2033
8.1. Middle East & Africa Inhaled Nitric Oxide Market Outlook, by Application, Value (US$ Bn), 2020-2033
8.1.1. Neonatal Respiratory Treatment
8.1.2. Chronic Obstructive Pulmonary Disease
8.1.3. Acute Respiratory Distress Syndrome
8.1.4. Others
8.2. Middle East & Africa Inhaled Nitric Oxide Market Outlook, by Country, Value (US$ Bn), 2020-2033
8.2.1. GCC Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
8.2.2. South Africa Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
8.2.3. Egypt Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
8.2.4. Nigeria Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
8.2.5. Rest of Middle East Inhaled Nitric Oxide Market Outlook, by Application, 2020-2033
8.3. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Mallinckrodt Pharmaceuticals
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. INO Therapeutics LLC
9.4.3. Air Products and Chemicals, Inc.
9.4.4. Vero Biotech LLC
9.4.5. Linde plc
9.4.6. Air Liquide S.A.
9.4.7. BOC Limited
9.4.8. Nikko Chemicals Co., Ltd.
9.4.9. Cryo Life, Inc.
9.4.10. GE Healthcare
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations